ASX-listed medical AI company Echo IQ has launched its cloud-based platform for structural heart disease screening in the United States.
A software platform called EchoSolv supports the identification of structural heart disease, including aortic stenosis defined by current guidelines, automating this process using AI. It can also complete bulk assessments at a rate of up to 48,000 per minute.
Other key features of the software include role-based access control for audit and usage traceability and optional SMS/email alerts for high-risk patients. It also comes as a web API for those who want to integrate it into their existing workflow to deliver results in real-time.
Given that severe aortic stenosis has a two-year mortality rate of 50% when untreated, it is important that high-risk patients are accurately identified using decision support tools.
“EchoSolv automates the identification of high-risk aortic stenosis patients. It heralds the beginning of a new era by increasing the cardiologist’s focus on patients at-risk without requiring any changes to the cardiac imaging solution, no new hardware, no new equipment, and no new disruptions and infrastructure which already exists,” said Professor David Playford, Echo IQ’s chief medical adviser.
The commercial launch of EchoSolv in the US comes as the company recently announced positive findings from a clinical study evaluating the effectiveness of the screening software. The study, conducted in partnership with Harvard Medical School’s Beth Israel Deaconess Medical Center, used EchoSolv to sift through 30,000 patient records. The final study showed that EchoSolv successfully identified a large group of patients with severe aortic stenosis, as well as those at risk of death from the condition.
The commercialization of EchoSolv was also supported by the appointment of Donald Fowler as president of Echo IQ USA. Fowler, who previously worked with Siemens Healthcare and Toshiba, is joining some of the country’s leading hospitals, ambulatory surgery centers, and health systems to sell his AI solutions.
Echo IQ is currently working to include additional conditions that EchoSolv can automatically identify, including heart failure, mitral regurgitation, and pulmonary hypertension.
On the record
“The launch of EchoSolv gives healthcare professionals a powerful new decision support tool to help patients who may benefit from proven therapies for severe aortic stenosis. to an additional layer of assessment to support more effective patient care,” commented Echo IQ chief commercial officer Deon Strydom.